Literature DB >> 23392862

Liver support systems: will they ever reach prime time?

Rafael Bañares1, María-Vega Catalina, Javier Vaquero.   

Abstract

Liver support systems aim to provide temporary support of liver function while maintaining extra-hepatic function in patients with liver failure. Important advances have been achieved in the design of artificial and bio-artificial devices, but the current systems are far from meeting the ideal. Artificial devices provide detoxification through different dialysis procedures, whereas bio-artificial devices add synthetic functions by incorporating a cellular component into the system. Overall, liver support systems have consistently shown beneficial effects on the pathophysiology of liver failure, especially in acute-on-chronic liver failure. However, these beneficial effects have not been translated into an improvement of survival. Our review discusses the current evidence, paying special attention to the clinical aspects of (bio)-artificial liver support devices.

Entities:  

Mesh:

Year:  2013        PMID: 23392862     DOI: 10.1007/s11894-013-0312-x

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  39 in total

1.  Burden of liver disease in the United States: summary of a workshop.

Authors:  W Ray Kim; Robert S Brown; Norah A Terrault; Hashem El-Serag
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

2.  Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome.

Authors:  Li-Min Guo; Jing-Yuan Liu; Dao-Zhen Xu; Bao-Shun Li; Hao Han; Ling-Hang Wang; Wei-Yan Zhang; Lian-He Lu; Xia Guo; Feng-Xia Sun; Hong-Yu Zhang; Xiao-Dong Liu; Jian-Ping Zhang; Yun Yao; Zhong-Ping He; Min-Min Wang
Journal:  Liver Int       Date:  2003       Impact factor: 5.828

3.  Continuous removal of middle molecules by hemofiltration in patients with acute liver failure.

Authors:  S Matsubara; K Okabe; K Ouchi; Y Miyazaki; Y Yajima; H Suzuki; M Otsuki; S Matsuno
Journal:  Crit Care Med       Date:  1990-12       Impact factor: 7.598

4.  Treatment with the molecular adsorbent recirculating system in patients with acute liver failure.

Authors:  M Felldin; S Friman; L Backman; A Siewert-Delle; B-A Henriksson; B Larsson; M Olausson
Journal:  Transplant Proc       Date:  2003-03       Impact factor: 1.066

5.  Removal selectivity of Prometheus: a new extracorporeal liver support device.

Authors:  Kinan Rifai; Thomas Ernst; Ulrich Kretschmer; Hermann Haller; Michael Peter Manns; Danilo Fliser
Journal:  World J Gastroenterol       Date:  2006-02-14       Impact factor: 5.742

6.  Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure.

Authors:  A J Ellis; R D Hughes; J A Wendon; J Dunne; P G Langley; J H Kelly; G T Gislason; N L Sussman; R Williams
Journal:  Hepatology       Date:  1996-12       Impact factor: 17.425

7.  High-flow-rate haemodiafiltration as a brain-support therapy proceeding to liver transplantation for hyperacute fulminant hepatic failure.

Authors:  Hiroshi Sadamori; Takahito Yagi; Masaru Inagaki; Yasuo Shima; Hiroaki Matsuda; Noriaki Tanaka; Kohsaku Sakaguchi; Takao Tsuji; Masaki Matsumi; Hiroshi Katayama; Norihisa Hirakawa
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-04       Impact factor: 2.566

8.  Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure.

Authors:  Achilles A Demetriou; Robert S Brown; Ronald W Busuttil; Jeffrey Fair; Brendan M McGuire; Philip Rosenthal; Jan Schulte Am Esch; Jan Lerut; Scott L Nyberg; Mauro Salizzoni; Elizabeth A Fagan; Bernard de Hemptinne; Christoph E Broelsch; Maurizio Muraca; Joan Manuel Salmeron; John M Rabkin; Herold J Metselaar; Daniel Pratt; Manuel De La Mata; Lawrence P McChesney; Gregory T Everson; Philip T Lavin; Anthony C Stevens; Zorina Pitkin; Barry A Solomon
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

9.  Hemodiabsorption in treatment of acute hepatic failure and chronic cirrhosis with ascites.

Authors:  S R Ash
Journal:  Artif Organs       Date:  1994-05       Impact factor: 3.094

10.  Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure.

Authors:  J G O'Grady; A E Gimson; C J O'Brien; A Pucknell; R D Hughes; R Williams
Journal:  Gastroenterology       Date:  1988-05       Impact factor: 22.682

View more
  4 in total

Review 1.  Cell therapy in chronic liver disease.

Authors:  Clara T Nicolas; Yujia Wang; Scott L Nyberg
Journal:  Curr Opin Gastroenterol       Date:  2016-05       Impact factor: 3.287

2.  Adverse events, short- and long-term outcomes of extra corporeal liver therapy in the intensive care unit: 16 years experience with MARS® in a single center.

Authors:  Clément Monet; Audrey De Jong; Yassir Aarab; Lauranne Piron; Albert Prades; Julie Carr; Fouad Belafia; Gérald Chanques; Boris Guiu; Georges-Philippe Pageaux; Samir Jaber
Journal:  Crit Care       Date:  2022-09-19       Impact factor: 19.334

Review 3.  Dental pulp cell bank as a possible future source of individual hepatocytes.

Authors:  Shogo Ohkoshi; Haruka Hirono; Taka Nakahara; Hiroshi Ishikawa
Journal:  World J Hepatol       Date:  2018-10-27

4.  Meta-analysis of individual patient data of albumin dialysis in acute-on-chronic liver failure: focus on treatment intensity.

Authors:  Rafael Bañares; Luis Ibáñez-Samaniego; Josep María Torner; Marco Pavesi; Carmen Olmedo; María Vega Catalina; Agustín Albillos; Fin Stolze Larsen; Frederik Nevens; Tarek Hassanein; Harmuth Schmidt; Uwe Heeman; Rajiv Jalan; Richard Moreau; Vicente Arroyo
Journal:  Therap Adv Gastroenterol       Date:  2019-09-27       Impact factor: 4.409

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.